PT Pyridam Farma Tbk (PYFA) said its financial performance in the\nthird quarter of 2026 included net revenue of Rp2.41 trillion, a 17.2\nper cent increase from Rp2.06 trillion in the same period last year.<\/p>\n
Chief Financial Officer Sinta Ningsih said the growth was supported\nby its Contract Development and Manufacturing Organization (CDMO)\nservices, which now operate in Indonesia and Australia.<\/p>\n
\u201cRevenue growth of 17.2 per cent, accompanied by a 29.9 per cent\nincrease in gross profit and a 91.5 per cent reduction in operating\nlosses, reflects the growing strength of our integrated manufacturing\nbusiness model and CDMO services,\u201d Sinta said in a statement in Jakarta\non Tuesday.<\/p>\n
Overall, she said, performance through the third quarter of 2026\nshowed an improvement in the quality of growth, not merely its scale.\nThe company\u2019s gross profit rose 29.9 per cent to Rp542.76 billion from\nRp417.86 billion, outpacing revenue growth.<\/p>\n
Sinta said the improvement continued at the operating level. The\ncompany\u2019s EBITDA reached Rp239.9 billion, up considerably from Rp8.8\nbillion in the same period last year. Depreciation and amortisation\ntotalled Rp252.7 billion, largely related to assets acquired from\nProbiotec, while financial expenses stood at Rp322.4 billion.<\/p>\n
As a result, the company still recorded a loss for the period of\nRp338.7 billion, although this was 7.4 per cent lower than in the\ncorresponding period last year. After foreign currency translation\ndifferences, the comprehensive loss narrowed by 27.8 per cent to Rp221.4\nbillion.<\/p>\n
\u201cResults through the third quarter of 2026 show that the integration\nof our expansion strategy and operational efficiencies over the past two\nyears is on the right track,\u201d she said.<\/p>\n
In September 2026, the company received marketing authorisation from\nIndonesia\u2019s Food and Drug Monitoring Agency (BPOM) for Fenofibrate 145\nmg, a product focused on treating lipid disorders and preventing\ncardiovascular problems.<\/p>\n
The product expands the company\u2019s cardiovascular therapy portfolio.\nAccording to BPJS Kesehatan data for January to September 2026, spending\non heart disease reached Rp17.35 trillion and spending on stroke Rp7.21\ntrillion. The product\u2019s contribution is expected to become evident in\nthe coming period as distribution progresses.<\/p>\n
The CDMO capabilities supporting the company\u2019s performance have been\ndeveloped gradually since its acquisition of Probiotec and the launch of\nCDMO services in 2024.<\/p>\n
The company\u2019s facility in Australia has obtained a licence from the\nTherapeutic Goods Administration (TGA), opening access to export markets\nwith international standards.<\/p>\n
The company has also completed the expansion of Sterile Injection\nLine 3 at PT Ethica Industri Farmasi. Commercial production is targeted\nto begin in 2027 to optimise installed capacity and generate revenue\nfrom CDMO services.<\/p>\n
\u201cWe are not only expanding the scale of our business in domestic and\nregional markets, but also consistently improving our operating cost\nstructure to accelerate the company\u2019s path to profitability,\u201d she\nadded.<\/p>", "url": "https:\/\/jawawa.id\/newsitem\/pt-pyfa-reports-17-2-revenue-growth-in-third-quarter-1793731880", "image": "" }, "sponsor": "Okusi Associates", "sponsor_url": "https:\/\/okusiassociates.com" }